Robust quarterly growth with reaffirmed guidance, significant share repurchases, and detailed executive insights on future strategies.
Despite a dip in Q1 performance, West Pharmaceutical projects a robust year with strategic expansions and improved guidance.
Explore the robust financial performance and strategic insights from CHDN's latest earnings call.